Compare Coupang Inc (CPNG) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Illumina, Inc. — how do they compare? Coupang Inc trades at $15.79 (market cap $27.70B), while Illumina, Inc. trades at $275.23 (market cap $39.95B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Illumina, Inc. for 83 Days on average.
| CPNG | ILMN | |
|---|---|---|
Market Cap | $27.70B | $39.95B |
Volume | 27,703,608 | 3,169,503 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $293.69 |
52-Week Low | $13.75 | $91.00 |
Typical Hold Time | 55 Days | 83 Days |
Enterprise Value | $27.22B | $41.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPNG trades at $15.83, up 6.89% over 24 hours, with a bullish technical signal from moving averages and ADX. The company reported $34.53B revenue in 2025 with a net income of $208M, though recent quarters show earnings misses. Analyst consensus is strongly bullish with a $25.25 price target, and cash flow from operations remains positive at $1.77B.
The outlook is mixed: strong revenue growth and analyst support offer upside, but negative net income margin and high P/E of 184.18 signal overvaluation risks. Key risks include competitive pressure from MercadoLibre and Alibaba, and a projected net loss of $767M in 2026. Institutional sentiment is positive, but earnings volatility requires caution.
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
